En studie av Belantamab Mafodotin monoterapi hos deltakere med myelomatose med normal og varierende grad av nedsatt nyrefunksjon (DREAMM12)
En fase I-studie for å evaluere farmakokinetikken og sikkerheten til Belantamab Mafodotin monoterapi hos deltakere med residiverende og/eller refraktært myelomatose (RRMM) som har normal og varierende grad av nedsatt nyrefunksjon (DREAMM 12)
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Fase 1
Utvidet tilgang
Utvidet tilgang
Tilgjengelig
- Tilgjengelig: Utvidet tilgang er for øyeblikket tilgjengelig for denne undersøkelsesbehandlingen, og pasienter som ikke er deltakere i den kliniske studien kan kanskje få tilgang til stoffet, biologisk eller medisinsk utstyr undersøkes.
- Ikke lenger tilgjengelig: Utvidet tilgang var tilgjengelig for denne intervensjonen tidligere, men er ikke tilgjengelig for øyeblikket og vil ikke være tilgjengelig i fremtiden.
- Midlertidig ikke tilgjengelig: Utvidet tilgang er for øyeblikket ikke tilgjengelig for denne intervensjonen, men forventes å være tilgjengelig i fremtiden.
- Godkjent for markedsføring: Intervensjonen har blitt godkjent av U.S. Food and Drug Administration for bruk av publikum.
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-post: GSKClinicalSupportHD@gsk.com
Studer Kontakt Backup
- Navn: EU GSK Clinical Trials Call Center
- Telefonnummer: +44 (0) 20 89904466
- E-post: GSKClinicalSupportHD@gsk.com
Studiesteder
-
-
-
Athens, Hellas, 10676
- GSK Investigational Site
-
Athens, Hellas, 11528
- GSK Investigational Site
-
-
-
-
-
Busan, Sør -Korea, 49241
- GSK Investigational Site
-
Seoul, Sør -Korea, 06591
- GSK Investigational Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Beskrivelse
Inklusjonskriterier:
- Deltakere er i stand til å gi signert informert samtykke som inkluderer overholdelse av kravene og begrensningene som er oppført i skjemaet for informert samtykke.
- Mannlige og/eller kvinnelige deltakere må være 18 år eller eldre på tidspunktet for undertegning av informert samtykke. I Republikken Korea må deltakerne være 19 år eller eldre på tidspunktet for undertegning av informert samtykke.
- Eastern Cooperative Oncology Group (ECOG) ytelsesstatus 0-2.
- Deltakere med histologisk eller cytologisk bekreftet diagnose av MM, som definert i International Myeloma Working Groups kriterier: 1. Har gjennomgått autolog stamcelletransplantasjon (SCT) eller anses som ikke-kvalifisert for transplantasjon; 2. Har mislyktes i minst 2 tidligere linjer med antimyelombehandlinger, inkludert et immunmodulerende medikament (eksempel [f.eks.], lenalidomid eller pomalidomid) og en proteasomhemmer (f.eks. bortezomib, ixazomib eller carfilzomib). I Republikken Korea bør deltakerne også ha residiverende eller refraktær sykdom etter behandling med et anti-CD38-antistoff, hvis tilgjengelig for pasienter, eller annen passende lokal behandlingsstandard.
- Deltakerne har målbar sykdom med minst ett av følgende: Serum M-protein >=0,5 gram per desiliter (g/dL) (>=5 gram per liter [g/L]); Urin M-protein >=200 milligram (mg) per 24 timer (mg/24 timer); og serumfri lett kjede (FLC)-analyse: Involvert FLC-nivå >=10 milligram per desiliter (mg/dL) (>=100 milligram per liter [mg/L]) og et unormalt serum-FLC-forhold (<0,26 eller >1,65) .
- Deltakere med en historie med autolog SCT er kvalifisert for studiedeltakelse forutsatt at følgende kvalifikasjonskriterier er oppfylt: 1. Transplantasjonen var >100 dager før studieregistreringen, 2. Ingen aktiv(e) infeksjon(er), og 3. Deltakeren oppfyller resten av kvalifikasjonskriterier skissert i denne protokollen.
- Deltakere med tilstrekkelig organsystemfunksjoner som definert som følger: Absolutt nøytrofiltall >=1,0 x 10^9 per liter (/L); Hemoglobin >=7,0 g/dL eller 4,9 millimol per liter (mmol/L); Blodplater >= 50 x 10^9/L; Total bilirubin <=1,5 x øvre normalgrense (ULN) (Isolert bilirubin >=1,5 x ULN er akseptabelt hvis bilirubin er fraksjonert og direkte bilirubin <35 prosent [%]); Alaninaminotransferase <=2,5 x ULN; iGFR, gruppe 1: normal/ lett svekket >=60 milliliter per minutt (ml/min); Gruppe 2: alvorlig 15-29 ml/min; Gruppe 3: ESRD (ikke i dialyse) <15 ml/min; Gruppe 4: ESRD (ved dialyse) <15 ml/min; og venstre ventrikkel ejeksjonsfraksjon ved ekkokardiogram >=40%.
- Hovedinkluderingskriterier i gruppe 1 (matchede kontrolldeltakere): Matchet til minst én deltaker med alvorlig nedsatt nyrefunksjon etter baseline kroppsvekt (+/-20%) og baseline albuminnivåer (+/-10%).
- Kvinnelige deltakere: Prevensjonsbruk av kvinner bør være i samsvar med lokale forskrifter angående prevensjonsmetoder for de som deltar i kliniske studier. En kvinnelig deltaker er kvalifisert til å delta hvis hun ikke er gravid eller ammer, og minst ett av følgende forhold gjelder: Er ikke en kvinne i fertil alder (WOCBP) ELLER er en WOCBP og bruker en prevensjonsmetode som er svært effektiv (med en feilrate på <1 % per år), fortrinnsvis med lav brukeravhengighet, under intervensjonsperioden og i minst 4 måneder etter siste dose av studieintervensjon og samtykker i å ikke donere egg (egg, oocytter) for reproduksjonsformål i løpet av denne perioden. Utforskeren bør evaluere effektiviteten av prevensjonsmetoden i forhold til den første dosen av studieintervensjon. En WOCBP må ha en negativ svært sensitiv serumgraviditetstest innen 72 timer etter dosering på syklus 1 dag 1 og godta å bruke svært effektiv prevensjon under studien og i 4 måneder etter siste dose med studiemedisin. Etterforskeren er ansvarlig for gjennomgang av sykehistorie, menstruasjonshistorie og nylig seksuell aktivitet for å redusere risikoen for inkludering av en kvinne med en tidlig uoppdaget graviditet.
- Mannlige deltakere: Prevensjonsbruk av menn bør være i samsvar med lokale forskrifter angående prevensjonsmetoder for de som deltar i kliniske studier. Mannlige deltakere er kvalifisert til å delta hvis de samtykker i følgende fra tidspunktet for første dose av studien til 6 måneder etter siste dose av studiebehandlingen for å tillate fjerning av endret sæd: Avstå fra å donere sæd og enten; Være avholdende fra heteroseksuelle samleie som deres foretrukne og vanlige livsstil (avholdende på langsiktig og vedvarende basis) og godta å forbli avholdende; ELLER må godta å bruke et mannlig kondom selv om de har gjennomgått en vellykket vasektomi og kvinnelig partner for å bruke en ekstra svært effektiv prevensjonsmetode med en feilrate på <1 % per år som når de har samleie med en WOCBP (inkludert gravide kvinner) .
Ekskluderingskriterier:
- Deltakere med aktiv plasmacelleleukemi på tidspunktet for screening. Symptomatisk amyloidose, aktivt POEMS-syndrom (polynevropati, organomegali, endokrinopati, myelomprotein og hudforandringer), Waldenstroem Makroglobulinemi
- Deltakerne hadde en tidligere allogen stamcelletransplantasjon. . Deltakere som har gjennomgått en syngen benmargstransplantasjon vil kun få tillatelse dersom det ikke er noen historie med eller ingen for øyeblikket aktive graft-versus-host-sykdommer (GvHD).
- Deltakeren har mottatt et undersøkelseslegemiddel innen 14 dager eller 5 halveringstider, avhengig av hva som er kortest, før den første dosen av studiemedikamentet. Dette inkluderer tidligere behandling med et monoklonalt antistoff. Det eneste unntaket er akuttbruk av en kort kur med systemiske kortikosteroider (tilsvarer eller mindre enn: deksametason 40 milligram per dag [mg/dag] i maksimalt 4 dager) før behandling.
- Tidligere belantamab-mafodotinbehandling.
- Deltakeren har mottatt en sterk organisk aniontransporterende polypeptidhemmer innen 14 dager eller 5 halveringstider, avhengig av hva som er kortest, før den første dosen av studiemedikamentet.
- Systemisk aktiv infeksjon som krever behandling.
- Eventuell uløst toksisitet >=grad 2 fra tidligere behandling bortsett fra alopecia eller perifer nevropati opp til grad 2.
- Plasmaferese innen 7 dager før første dose av studiemedikamentet. Screening av laboratorieverdier må utføres etter siste plasmaferese.
- Enhver større operasjon i løpet av de siste 4 ukene før dag 1 av screening.
- Enhver alvorlig og/eller ustabil eksisterende medisinsk, psykiatrisk lidelse eller andre tilstander (inkludert laboratorieavvik unntatt nyresvikt) som kan forstyrre deltakerens sikkerhet, innhenting av informert samtykke eller overholdelse av studieprosedyrene.
- Bevis på aktiv slimhinneblødning eller indre blødning.
- Gjeldende ustabil lever- eller gallesykdom per etterforskers vurdering definert av tilstedeværelsen av ascites, encefalopati, koagulopati, hypoalbuminemi, esophageal eller gastrisk varicer, vedvarende gulsott eller skrumplever. (Stabil kronisk leversykdom [(inkludert Gilberts syndrom eller asymptomatiske gallestein]) eller hepatobiliær involvering av malignitet er akseptabelt dersom deltakeren ellers oppfyller inngangskriteriene)
- Deltakere med tidligere eller samtidige maligniteter andre enn MM er ekskludert, med mindre den tidligere maligniteten har blitt ansett som medisinsk stabil i minst 2 år. Deltakeren må ikke motta aktiv terapi, annet enn hormonbehandling for denne sykdommen. (Deltakere med kurativt behandlet ikke-melanom hudkreft er tillatt uten 2-års begrensning)
- Bevis på kardiovaskulær risiko, inkludert noen av følgende: Bevis på aktuelle klinisk signifikante ubehandlede arytmier, inkludert klinisk signifikante elektrokardiogramavvik som annengrads (Mobitz Type II) eller tredjegrads atrioventrikulær blokkering; Anamnese med hjerteinfarkt (i løpet av de siste 18 måneder), akutte koronare syndromer (inkludert ustabil angina), koronar angioplastikk eller stenting eller bypass-transplantasjon innen 3 måneder etter screening; Klasse III eller IV hjertesvikt som definert av New York Heart Association funksjonelle klassifiseringssystem og ukontrollert hypertensjon.
- Kjent umiddelbar eller forsinket overfølsomhetsreaksjon eller idiosynkratisk reaksjon på legemidler som er kjemisk relatert til belantamab mafodotin, eller noen av komponentene i studiebehandlingen.
- Kjent infeksjon med humant immunsviktvirus, med mindre deltakeren kan oppfylle alle følgende kriterier: Etablert antiretroviral terapi (ART) i minst 4 uker og HIV-virusmengde <400 kopier/ml før første dose; CD4+ T-celle (CD4+) teller ≥350 celler/L og ingen historie med AIDS-definerende opportunistiske infeksjoner i løpet av de siste 12 månedene
- Deltakere med hepatitt B vil bli ekskludert med mindre følgende kriterier kan oppfylles: Hvis deltakeren er hepatitt B kjerneantistoff (HbcAb) positiv eller hepatitt B overflateantigen (HbsAg) negativ, bør hepatitt B virus (HBV) deoksyribonukleinsyre (DNA) være uoppdagelig på tidspunktet for screening; Hvis HbsAg+ ved screening eller <=3 måneder før første dose av studiebehandlingen, bør HBV-DNA være upåviselig, høyeffektiv antiviral behandling bør startes ≥4 uker før første dose av studiebehandlingen. Deltakere med skrumplever er ekskludert.
- Positivt hepatitt C-antistoff-testresultat eller positivt hepatitt C-ribonukleinsyretestresultat ved screening eller innen 3 måneder før første dose av studiebehandlingen med mindre deltakeren kan oppfylle følgende kriterier: RNA-test negativ og vellykket antiviral behandling (vanligvis 8 ukers varighet) ) er nødvendig, etterfulgt av en negativ HCV RNA-test etter en utvaskingsperiode på minst 4 uker før første dose.
- Deltakere med nedsatt nyrefunksjon på grunn av leversykdom (hepatorenalt syndrom).
- Nåværende epitelsykdom i hornhinnen bortsett fra mild punctuate keratopati.
- Deltaker er en kvinne som er gravid eller ammer.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Del 1: Deltakere med normal/lett nedsatt nyrefunksjon
Deltakere med normal eller lett nedsatt nyrefunksjon (Normal: individuell glomerulær filtrasjonshastighet [iGFR]: >=90 milliliter per minutt; Lett svekkelse: iGFR: 60-89 ml/min vil bli administrert med belantamab mafodotin 2,5 mg/kg som en intravenøs infusjon over 30 minutter Q3W på dag 1 av hver 21-dagers syklus til bekreftet sykdomsprogresjon, død, uakseptabel toksisitet, tilbaketrekking av samtykke eller slutten av studien, avhengig av hva som inntreffer først.
|
Belantamab mafodotin vil bli levert som frysetørret pulver som vil være tilgjengelig som 100 milligram per hetteglass (mg/hetteglass) i engangs hetteglass for rekonstituering.
Lyofilisert belantamab mafodotin vil rekonstitueres med vann til injeksjon, fortynnes med vanlig 0,9 % saltvann før bruk.
Andre navn:
|
|
Eksperimentell: Del 1: Deltakere med alvorlig nedsatt nyrefunksjon
Deltakere med alvorlig nedsatt nyrefunksjon (iGFR: 15-29 ml/min) vil bli administrert med belantamab mafodotin 2,5 mg/kg som en intravenøs infusjon over 30 minutter Q3W på dag 1 av hver 21-dagers syklus inntil bekreftet sykdomsprogresjon, død, uakseptabel toksisitet, tilbaketrekking av samtykke eller slutten av studien, avhengig av hva som inntreffer først.
|
Belantamab mafodotin vil bli levert som frysetørret pulver som vil være tilgjengelig som 100 milligram per hetteglass (mg/hetteglass) i engangs hetteglass for rekonstituering.
Lyofilisert belantamab mafodotin vil rekonstitueres med vann til injeksjon, fortynnes med vanlig 0,9 % saltvann før bruk.
Andre navn:
|
|
Eksperimentell: Del 2: Deltakere med ESRD (ikke i dialyse)
Deltakere med ESRD (iGFR: <15 ml/min) som ikke er i dialyse, vil bli administrert med belantamab mafodotin enten 2,5 mg/kg eller 1,9 mg/kg (eller annen justert dose) som en intravenøs infusjon over 30 minutter Q3W på dag 1 av hver 21-dagers syklus til bekreftet sykdomsprogresjon, død, uakseptabel toksisitet, tilbaketrekking av samtykke eller avsluttet studie, avhengig av hva som inntreffer først.
I del 2 vil dosen bestemmes etter evaluering av farmakokinetiske data og sikkerhetsdata i del 1.
|
Belantamab mafodotin vil bli levert som frysetørret pulver som vil være tilgjengelig som 100 milligram per hetteglass (mg/hetteglass) i engangs hetteglass for rekonstituering.
Lyofilisert belantamab mafodotin vil rekonstitueres med vann til injeksjon, fortynnes med vanlig 0,9 % saltvann før bruk.
Andre navn:
|
|
Eksperimentell: Del 2: Deltakere med ESRD (om hemodialyse)
Deltakere med ESRD (iGFR: <15 ml/min) på hemodialyse vil bli administrert med belantamab mafodotin enten 2,5 mg/kg eller 1,9 mg/kg (eller annen justert dose) som en intravenøs infusjon over 30 minutter Q3W på dag 1 av hver 21. -dagers syklus frem til bekreftet sykdomsprogresjon, død, uakseptabel toksisitet, tilbaketrekking av samtykke eller avsluttet studie, avhengig av hva som inntreffer først.
I del 2 vil dosen bestemmes etter evaluering av farmakokinetiske data og sikkerhetsdata i del 1.
|
Belantamab mafodotin vil bli levert som frysetørret pulver som vil være tilgjengelig som 100 milligram per hetteglass (mg/hetteglass) i engangs hetteglass for rekonstituering.
Lyofilisert belantamab mafodotin vil rekonstitueres med vann til injeksjon, fortynnes med vanlig 0,9 % saltvann før bruk.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Part 1: Area Under the Concentration-time Curve to Last Quantifiable Timepoint (AUC(0-tlast)) Following Administration of Belantamab Mafodotin (Antibody-drug Conjugate (ADC))
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
Blood samples were collected for PK analysis of belantamab mafodotin ADC.
As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
Only those participants who were measured and analyzed (i.e., contributed to data reported in the table) were included in the Overall Number of Participants Analyzed field.
'Number Analyzed' signifies participants evaluable for the specified timepoints.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
|
Part 1: Area Under the Concentration-time Curve During the Dosing Interval (AUC(0-tau)) Following Administration of Belantamab Mafodotin (ADC)
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
Blood samples were collected for PK analysis of belantamab mafodotin ADC.
As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
|
Part 1: Observed Plasma Concentration at the End of Infusion (C-EOI) Following Administration of Belantamab Mafodotin (ADC)
Tidsramme: End of infusion on C1D1 and C3D1
|
Blood samples were collected for PK analysis of belantamab mafodotin ADC.
As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.
|
End of infusion on C1D1 and C3D1
|
|
Part 1: Maximum Observed Concentration (Cmax) Following Administration of Belantamab Mafodotin (ADC)
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
Blood samples were collected for PK analysis of belantamab mafodotin ADC.
As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
|
Part 1: Time to Reach Cmax (Tmax) Following Administration of Belantamab Mafodotin (ADC)
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
Blood samples were collected for PK analysis of belantamab mafodotin ADC.
As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
|
Part 1: Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) Following Administration of Belantamab Mafodotin (ADC)
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
Blood samples were collected for PK analysis of belantamab mafodotin ADC.
As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
|
Part 1: Time of Last Observed Quantifiable Concentration (Tlast) Following Administration of Belantamab Mafodotin (ADC)
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1 (up to Day 30 in C1 and C3)
|
Blood samples were collected for PK analysis of belantamab mafodotin ADC.
As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
For some participants, dosing in Cycle 2 or Cycle 4 was delayed, resulting in the pre-dose samples in these cycles (C2D1 or C4D1) being collected later than the protocol-defined planned days after dosing in C1D1 or C3D1.
Consequently, the last PK samples for these participants were collected outside the pre-defined protocol time points, and certain Tlast values in the data table extend beyond the original protocol-defined Time Frame.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1 (up to Day 30 in C1 and C3)
|
|
Part 1: Area Under the Concentration-time Curve to Last Quantifiable Timepoint (AUC(0-tlast)) Following Administration of Belantamab Mafodotin (Total Antibody)
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody.
As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
|
Part 1: Area Under the Concentration-time Curve During the Dosing Interval (AUC(0-tau)) Following Administration of Belantamab Mafodotin (Total Antibody)
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
Blood samples were collected for PK analysis of belantamab mafodotin total Antibody.
As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
|
Part 1: Observed Plasma Concentration at the End of Infusion (C-EOI) Following Administration of Belantamab Mafodotin (Total Antibody)
Tidsramme: End of infusion on C1D1 and C3D1
|
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody.
As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.
|
End of infusion on C1D1 and C3D1
|
|
Part 1: Maximum Observed Concentration (Cmax) Following Administration of Belantamab Mafodotin (Total Antibody)
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody.
As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
|
Part 1: Time to Reach Cmax (Tmax) Following Administration of Belantamab Mafodotin (Total Antibody)
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
Blood samples were collected for PK analysis of belantamab mafodotin total antibody.
As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
|
Part 1: Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) Following Administration of Belantamab Mafodotin (Total Antibody)
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody.
As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
|
Part 1: Time of Last Observed Quantifiable Concentration (Tlast) Following Administration of Belantamab Mafodotin (Total Antibody)
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1 (up to Day 30 in C1 and C3)
|
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody.
As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
For some participants, dosing in Cycle 2 or Cycle 4 was delayed, resulting in the pre-dose samples in these cycles (C2D1 or C4D1) being collected later than the protocol-defined planned days after dosing in C1D1 or C3D1.
Consequently, the last PK samples for these participants were collected outside the pre-defined protocol time points, and certain Tlast values in the data table extend beyond the original protocol-defined Time Frame.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1 (up to Day 30 in C1 and C3)
|
|
Part 1: Area Under the Concentration-time Curve to Last Quantifiable Timepoint (AUC(0-tlast)) Following Administration of Belantamab Mafodotin (Cysteine Maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF))
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF.
As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
|
Part 1: Area Under the Concentration-time Curve During the Dosing Interval up to 168 Hours (AUC (0-168h)) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, and D15; Anytime on C3 D4, D8, and D15
|
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF.
As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.
In cases where the nominal Day 8 sample was collected prior to 168 hours and earlier time points did not permit reliable extrapolation to 168 hours, a later sample (e.g., Day 15) with a measurable concentration was used to support estimation of the concentration at 168 hours.
Outcome data are reported only for AUC over 0-168 hours.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, and D15; Anytime on C3 D4, D8, and D15
|
|
Part 1: Observed Plasma Concentration at the End of Infusion (C-EOI) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)
Tidsramme: End of infusion on C1D1 and C3D1
|
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF.
As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.
|
End of infusion on C1D1 and C3D1
|
|
Part 1: Maximum Observed Concentration (Cmax) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF.
As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
|
Part 1: Time to Reach Cmax (Tmax) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF.
As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
|
Part 1: Time of Last Observed Quantifiable Concentration (Tlast) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF.
As pre-specified in protocol, only specified treatment arms were planned to be analyzed for this outcome measure.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
|
Part 2: Area Under the Concentration-time Curve to Last Quantifiable Timepoint (AUC(0-tlast)) Following Administration of Belantamab Mafodotin (Antibody-drug Conjugate (ADC))
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
Blood samples were collected for PK analysis of belantamab mafodotin ADC.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
|
Part 2: Area Under the Concentration-time Curve During the Dosing Interval (AUC(0-tau)) Following Administration of Belantamab Mafodotin (ADC)
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
Blood samples were collected for PK analysis of belantamab mafodotin ADC.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
|
Part 2: Observed Plasma Concentration at the End of Infusion (C-EOI) Following Administration of Belantamab Mafodotin (ADC)
Tidsramme: End of infusion on C1D1 and C3D1
|
Blood samples were collected for PK analysis of belantamab mafodotin ADC.
|
End of infusion on C1D1 and C3D1
|
|
Part 2: Maximum Observed Concentration (Cmax) Following Administration of Belantamab Mafodotin (ADC)
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
Blood samples were collected for PK analysis of belantamab mafodotin ADC.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
|
Part 2: Time to Reach Cmax (Tmax) Following Administration of Belantamab Mafodotin (ADC)
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
Blood samples were collected for PK analysis of belantamab mafodotin ADC.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
|
Part 2: Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) Following Administration of Belantamab Mafodotin (ADC)
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
Blood samples were collected for PK analysis of belantamab mafodotin ADC.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
|
Part 2: Time of Last Observed Quantifiable Concentration (Tlast) Following Administration of Belantamab Mafodotin (ADC)
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1 (up to Day 30 in C1 and C3)
|
Blood samples were collected for PK analysis of belantamab mafodotin ADC.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
For some participants, dosing in Cycle 2 or Cycle 4 was delayed, resulting in the pre-dose samples in these cycles (C2D1 or C4D1) being collected later than the protocol-defined planned days after dosing in C1D1 or C3D1.
Consequently, the last PK samples for these participants were collected outside the pre-defined protocol time points, and certain Tlast values in the data table extend beyond the original protocol-defined Time Frame.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1 (up to Day 30 in C1 and C3)
|
|
Part 2: Area Under the Concentration-time Curve to Last Quantifiable Timepoint (AUC(0-tlast)) Following Administration of Belantamab Mafodotin (Total Antibody)
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
|
Part 2: Area Under the Concentration-time Curve During the Dosing Interval (AUC(0-tau)) Following Administration of Belantamab Mafodotin (Total Antibody)
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
|
Part 2: Observed Plasma Concentration at the End of Infusion (C-EOI) Following Administration of Belantamab Mafodotin (Total Antibody)
Tidsramme: End of infusion on C1D1 and C3D1
|
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody.
|
End of infusion on C1D1 and C3D1
|
|
Part 2: Maximum Observed Concentration (Cmax) Following Administration of Belantamab Mafodotin (Total Antibody)
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
|
Part 2: Time to Reach Cmax (Tmax) Following Administration of Belantamab Mafodotin (Total Antibody)
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
|
Part 2: Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) Following Administration of Belantamab Mafodotin (Total Antibody)
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
|
Part 2: Time of Last Observed Quantifiable Concentration (Tlast) Following Administration of Belantamab Mafodotin (Total Antibody)
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1 (up to Day 30 in C1 and C3)
|
Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
For some participants, dosing in Cycle 2 or Cycle 4 was delayed, resulting in the pre-dose samples in these cycles (C2D1 or C4D1) being collected later than the protocol-defined planned days after dosing in C1D1 or C3D1.
Consequently, the last PK samples for these participants were collected outside the pre-defined protocol time points, and certain Tlast values in the data table extend beyond the original protocol-defined Time Frame.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1 (up to Day 30 in C1 and C3)
|
|
Part 2: Area Under the Concentration-time Curve to Last Quantifiable Timepoint (AUC(0-tlast)) Following Administration of Belantamab Mafodotin (Cysteine Maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF))
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
|
Part 2: Area Under the Concentration-time Curve During the Dosing Interval up to 168 Hours (AUC (0-168h)) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, and D15; Anytime on C3 D4, D8, and D15
|
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF.
In cases where the nominal Day 8 sample was collected prior to 168 hours and earlier time points did not permit reliable extrapolation to 168 hours, a later sample (e.g., Day 15) with a measurable concentration was used to support estimation of the concentration at 168 hours.
Outcome data are reported only for AUC over 0-168 hours.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, and D15; Anytime on C3 D4, D8, and D15
|
|
Part 2: Observed Plasma Concentration at the End of Infusion (C-EOI) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)
Tidsramme: End of infusion on C1D1 and C3D1
|
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF.
|
End of infusion on C1D1 and C3D1
|
|
Part 2: Maximum Observed Concentration (Cmax) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
|
Part 2: Time to Reach Cmax (Tmax) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
|
Part 2: Time of Last Observed Quantifiable Concentration (Tlast) Following Administration of Belantamab Mafodotin (Cys-mcMMAF)
Tidsramme: Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
Blood samples were collected for PK analysis of belantamab mafodotin Cys-mcMMAF.
As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.
|
Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Part 1 and Part 2: Change From Baseline (CFB) in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)
Tidsramme: Baseline (Day 1) and up to approx. 236 weeks
|
Blood pressures (DBP and SBP) were measured after resting for at least 5 minutes in a supine or semi-recumbent position.
Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits.
Change from Baseline was calculated as post-dose visit value minus Baseline value.
The "0" participants analyzed represents that data was not collected or available for analysis at that particular time point for the respective Arms/Groups.
|
Baseline (Day 1) and up to approx. 236 weeks
|
|
Part 1 and Part 2: Change From Baseline (CFB) in Vital Signs: Heart Rate
Tidsramme: Baseline (Day 1) and up to approx. 236 weeks
|
Heart rate was measured after resting for at least 5 minutes in a supine or semi-recumbent position.
Baseline (Day 1) was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits.
Change from Baseline was calculated as post-dose visit value minus Baseline value.
|
Baseline (Day 1) and up to approx. 236 weeks
|
|
Part 1 and Part 2: Number of Participants With Adverse Events (AEs)
Tidsramme: Up to approximately 236 weeks
|
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.
AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.
|
Up to approximately 236 weeks
|
|
Part 1 and Part 2: Number of Participants With Worst Case Hematology Results by Maximum Grade Increase Post-Baseline Relative to Baseline
Tidsramme: Baseline (Day 1) and up to approx. 236 weeks
|
Blood samples were collected for the analysis of hematology parameters and are categorized in alignment with Common Terminology Criteria for Adverse Events (CTCAE) version 5 as Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; and Grade 4: life-threatening consequences.
Higher grade indicates greater severity.
An increase in grade was defined relative to the Baseline grade.
Participants with missing baseline values are assumed to have baseline value of grade 0. Increase to a maximum grade of 3 and 4 is presented.
Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
|
Baseline (Day 1) and up to approx. 236 weeks
|
|
Part 1 and Part 2: Number of Participants With Worst Case Clinical Chemistry Results by Maximum Grade Increase Post-Baseline Relative to Baseline
Tidsramme: Baseline (Day 1) and up to approx. 236 weeks
|
Blood samples were collected for the analysis of clinical chemistry parameters and are categorized in alignment with Common Terminology Criteria for Adverse Events (CTCAE) version 5 as Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; and Grade 4: life-threatening consequences.
Higher grade indicates greater severity.
An increase in grade was defined relative to the Baseline grade.
Participants with missing baseline values are assumed to have baseline value of grade 0. Increase to a maximum grade of 3 and 4 is presented.
Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
|
Baseline (Day 1) and up to approx. 236 weeks
|
|
Part 1 and Part 2: Change From Baseline (CFB) in Weight
Tidsramme: Baseline (Day 1) and up to approx. 236 weeks
|
Physical examination parameter weight was assessed.
Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline
|
Baseline (Day 1) and up to approx. 236 weeks
|
|
Part 1 and Part 2: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline
Tidsramme: Baseline (Day 1) and up to approx. 236 weeks
|
Urine samples were collected to assess occult blood and protein in urine by dipstick method.
Data is presented as "No Change/Decreased" and "Any Increase" that includes Increase to TRACE, Increase to 1+, Increase to 2+ and Increase to 3+ indicating proportional concentrations in the urine sample.
Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.
|
Baseline (Day 1) and up to approx. 236 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Studieleder: GSK Clinical Trials, GlaxoSmithKline
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Vaskulære sykdommer
- Kardiovaskulære sykdommer
- Patologiske prosesser
- Neoplasmer
- Mannlige urogenitale sykdommer
- Nyresykdommer
- Urologiske sykdommer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Kronisk sykdom
- Sykdomsattributter
- Sykdommer i immunsystemet
- Neoplasmer etter histologisk type
- Hematologiske sykdommer
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Neoplasmer, plasmacelle
- Hemostatiske lidelser
- Paraproteinemier
- Blodproteinforstyrrelser
- Hemoragiske lidelser
- Nyresvikt, kronisk
- Patologiske tilstander, tegn og symptomer
- Hemic og lymfatiske sykdommer
- Multippelt myelom
- Nyreinsuffisiens
- Nyresvikt, kronisk
- Belantamab mafodotin
Andre studie-ID-numre
Andre studie-ID-numre
- 209626
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
Tilgangskriterier for IPD-deling
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .